Get the Stockscreener App
17.53
0.63%
0.08
After Hours:
17.53
Eton Pharmaceuticals Inc stock is traded at $17.53, with a volume of 199.85K.
It is up +0.63% in the last 24 hours and up +19.05% over the past month.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
See More
Previous Close:
$17.45
Open:
$17.62
24h Volume:
199.85K
Relative Volume:
0.81
Market Cap:
$470.11M
Revenue:
$31.38M
Net Income/Loss:
$-6.69M
P/E Ratio:
-67.42
EPS:
-0.26
Net Cash Flow:
$-1.84M
1W Performance:
-0.51%
1M Performance:
+19.05%
6M Performance:
-1.73%
1Y Performance:
+15.68%
1-Day Range:
$17.29
$18.23
1-Week Range:
$16.68
$18.47
52-Week Range:
$11.09
$23.00
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Name
Eton Pharmaceuticals Inc
Sector
Phone
(847) 787-7361
Address
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
17.53 | 467.97M | 31.38M | -6.69M | -1.84M | -0.26 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.98 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Reiterated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | B. Riley Securities | Buy |
| Jan-06-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-04-24 | Resumed | H.C. Wainwright | Buy |
| May-06-24 | Initiated | Craig Hallum | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Jan-04-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-20-19 | Initiated | B. Riley FBR | Buy |
| Jun-10-19 | Initiated | H.C. Wainwright | Buy |
View All
Eton Pharmaceuticals Inc Stock (ETON) Latest News
HC Wainwright Issues Pessimistic Outlook for ETON Earnings - MarketBeat
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Date and Conference Call Details - Quiver Quantitative
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, ... - Bluefield Daily Telegraph
Eton inks deal to sell its 10th rare disease drug - Crain's Chicago Business
Craig Hallum Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price - MarketBeat
Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum - TipRanks
Eton Pharmaceuticals acquires U.S. rights to hemangioma drug By Investing.com - Investing.com Canada
Eton Pharmaceuticals Acquires US Commercialization Rights to Pierre Fabre's Hemangeol - marketscreener.com
HC Wainwright Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock - MarketBeat
Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL - TipRanks
Eton Pharmaceuticals, Inc. announced that, in addition to the acquisition of core assets, the company also plans to purchase approximately $1.5 million worth of inventory products at the time of transaction closing. - Bitget
Understanding Momentum Shifts in (ETON) - Stock Traders Daily
Lumbard & Kellner LLC Buys New Holdings in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution - Benzinga
Only FDA-approved infantile hemangioma drug moves to Eton with $0 co-pays - Stock Titan
Eton Pharmaceuticals (NASDAQ: ETON) licenses U.S. HEMANGEOL rights in orphan drug deal - Stock Titan
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution - Sahm
Eton Pharmaceuticals' DESMODA Receives FDA Approval - Intellectia AI
US FDA approves Eton Pharma’s hormonal disorder drug - 1470 & 100.3 WMBD
Eton Pharmaceuticals Receives FDA Approval for New Drug Launch - Intellectia AI
Eton Reports US FDA Approval for Desmoda Oral Solution - marketscreener.com
Eton Pharmaceuticals Wins FDA Approval for DESMODA Therapy - TipRanks
Eton wins FDA nod for rare disorder therapy Desmoda (ETON) - Seeking Alpha
US FDA approves Eton's liquid therapy for rare water-balance disorder - Reuters
US FDA approves Eton Pharma's hormonal disorder drug - AOL.com
Eton Pharmaceuticals Launches DESMODA™, First FDA-Approved Oral Solution for Central Diabetes Insipidus - Quiver Quantitative
FDA clears first liquid desmopressin for rare water-balance disorder - Stock Titan
US FDA approves Eton’s liquid therapy for rare water-balance disorder - whbl.com
ETON Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
FDA To Decide On ET-600 On February 25: Will It Mark Eton's Ninth Commercial Product? - RTTNews
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th - The Manila Times
Rare-disease drug maker Eton to meet attendees at Leerink conference - Stock Titan
February 2026's Top Growth Companies With Insider Influence - simplywall.st
Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment - MSN
What are Eton Pharmaceuticals Inc.’s technical support levelsJuly 2025 Big Picture & Real-Time Stock Entry Alerts - mfd.ru
Volatility Watch: Is Eton Pharmaceuticals Inc a cyclical or defensive stockGap Up & Safe Entry Zone Identification - baoquankhu1.vn
Activity Recap: Is Eton Pharmaceuticals Inc. still a buy after recent gains - mfd.ru
Eton Pharmaceuticals (ETON) Investor Outlook: A Small-Cap Biotech with a 78.68% Potential Upside - DirectorsTalk Interviews
What drives Eton Pharmaceuticals Inc.’s stock priceEarnings Miss & Weekly High Potential Stock Alerts - mfd.ru
We Might See A Profit From Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Soon - simplywall.st
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of "Hold" by Analysts - MarketBeat
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Hold” by Analysts - Defense World
Analysts Are Bullish on These Healthcare Stocks: Eton Pharmaceuticals (ETON), HealthStream (HSTM) - The Globe and Mail
Eton Pharmaceuticals stock rises after licensing ultra-rare disease drug By Investing.com - Investing.com South Africa
Eton Pharmaceuticals stock rises after licensing ultra-rare disease drug - Investing.com India
Eton Pharmaceuticals Licenses US Marketing Rights to Ultra-Rare Disease Product - marketscreener.com
Eton Pharmaceuticals licenses ultra-rare disease treatment candidate - Investing.com
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate - The Manila Times
Eton Pharmaceuticals licenses ultra-rare disease treatment candidate By Investing.com - Investing.com UK
Eton Pharmaceuticals Licenses U.S. Marketing Rights for Ultra-Rare Disease Product Candidate, Anticipates FDA Approval by Mid-2026 - Quiver Quantitative
Eton Pharmaceuticals Inc Stock (ETON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
1.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):